Analysts project $142.86 average target as Encompass Health sets Feb. 5 Q4 report
Eleven analysts covering Encompass Health have issued an average “Buy” rating, including eight buys, two strong buys and one hold, with a mean 12-month target of $142.8571. The company will report Q4 2025 results on Feb. 5, 2026, with an investor call on Feb. 6.
1. Analyst Consensus and Price Targets
Eleven analysts currently cover Encompass Health, assigning an average recommendation of Buy. Eight issued buy ratings, two issued strong buy ratings and one issued a hold rating. Over the past 12 months, the average twelve-month target price stood at $142.86, indicating roughly 27% upside from recent trading levels. This consensus reflects confidence in the company’s post-acute care network expansion and steady cash flow generation.
2. Recent Ratings and Price Target Revisions
Raymond James upgraded its view to strong buy on October 31st, reflecting anticipated same-store revenue growth in inpatient rehabilitation. Barclays raised its target from $141 to $150 and maintained an overweight rating on October 30th, citing margin expansion potential. KeyCorp lifted its target from $135 to $140 on September 16th, highlighting positive reimbursement trends. Conversely, Wall Street Zen moved from buy to hold on November 1st, questioning near-term reimbursement headwinds, while Weiss Ratings reiterated its buy (B+) stance on October 8th.
3. Financial Metrics and Performance
Encompass Health reported $0.93 in earnings per share for the most recent quarter on revenue of $136.3 million, delivering a net margin of 9.33% and return on equity of 17.84%. The company carries a quick ratio of 1.14, a current ratio of 1.14 and a debt-to-equity ratio of 0.76. Its market capitalization stands at $10.35 billion, with a price-to-earnings ratio of 19.45, a P/E/G ratio of 1.69 and a beta of 0.74. Share price has traded between $90.67 and $127.99 over the past 52 weeks, with 50-day and 200-day simple moving averages at $110.79 and $117.02 respectively.
4. Q4 Earnings Call and Dividend Announcement
The company will release results for the quarter ended December 31st after market close on February 5th and will host an investor conference call at 10 a.m. ET on February 6th. A webcast and replay will be available on the corporate website. Encompass Health declared a quarterly dividend of $0.19 per share, payable January 15th to holders of record as of January 2nd, equating to an annualized payout of $0.76 and a yield of 0.7%. The current dividend payout ratio is 14.37%.